SI9200297B - Antagonisti endotelinskih receptorjev - Google Patents

Antagonisti endotelinskih receptorjev Download PDF

Info

Publication number
SI9200297B
SI9200297B SI9200297A SI9200297A SI9200297B SI 9200297 B SI9200297 B SI 9200297B SI 9200297 A SI9200297 A SI 9200297A SI 9200297 A SI9200297 A SI 9200297A SI 9200297 B SI9200297 B SI 9200297B
Authority
SI
Slovenia
Prior art keywords
hydrogen
alkyl
methylenedioxyphenyl
methoxyphenyl
formula
Prior art date
Application number
SI9200297A
Other languages
English (en)
Slovenian (sl)
Other versions
SI9200297A (en
Inventor
Donovan Russell Cousins
Duncah John Elliott
Amparo Maria Lago
Dale Jack Leber
Elizabeth Catherine Peishoff
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of SI9200297A publication Critical patent/SI9200297A/sl
Publication of SI9200297B publication Critical patent/SI9200297B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI9200297A 1991-11-05 1992-11-03 Antagonisti endotelinskih receptorjev SI9200297B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78787091A 1991-11-05 1991-11-05
US85419592A 1992-03-20 1992-03-20

Publications (2)

Publication Number Publication Date
SI9200297A SI9200297A (en) 1993-06-30
SI9200297B true SI9200297B (sl) 2003-02-28

Family

ID=27120702

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9200297A SI9200297B (sl) 1991-11-05 1992-11-03 Antagonisti endotelinskih receptorjev

Country Status (33)

Country Link
EP (1) EP0612244B1 (fr)
JP (1) JP2667294B2 (fr)
KR (1) KR100342960B1 (fr)
CN (2) CN1034569C (fr)
AP (1) AP433A (fr)
AT (1) ATE205711T1 (fr)
AU (1) AU669866B2 (fr)
BG (1) BG61523B1 (fr)
BR (1) BR9206722A (fr)
CA (1) CA2122820A1 (fr)
CZ (1) CZ287406B6 (fr)
DE (1) DE69232072T2 (fr)
DK (1) DK0612244T3 (fr)
ES (1) ES2164054T3 (fr)
FI (1) FI942059A (fr)
HK (1) HK1012251A1 (fr)
HU (1) HUT67665A (fr)
IL (1) IL103621A0 (fr)
MA (1) MA22758A1 (fr)
MX (1) MX9206348A (fr)
MY (1) MY108579A (fr)
NO (1) NO304887B1 (fr)
NZ (1) NZ245000A (fr)
OA (1) OA09921A (fr)
PL (1) PL176250B1 (fr)
PT (1) PT101038B (fr)
RO (1) RO117847B1 (fr)
RU (1) RU2125980C1 (fr)
SI (1) SI9200297B (fr)
SK (1) SK282098B6 (fr)
TW (1) TW298590B (fr)
UA (1) UA44686C2 (fr)
WO (1) WO1993008799A1 (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
US5817693A (en) 1991-11-05 1998-10-06 Cousins; Russell Donovan Endothelin receptor antagonists
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
AU4376893A (en) * 1992-05-19 1993-12-13 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
ES2062927B1 (es) * 1992-12-17 1995-07-01 Smithkline Beecham Corp Antagonistas de los receptores de endotelina y procedimiento para su preparacion.
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
GB9307694D0 (en) * 1993-04-14 1993-06-02 Smithkine Beecham Corp Novel compounds
FI941826A (fi) 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
CZ291189B6 (cs) * 1993-04-27 2003-01-15 Smithkline Beecham Corporation Indanové a indenové deriváty jako antagonisty receptorů endothelinu, způsob jejich přípravy, farmaceutický prostředek a pouľití
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
EP0723449A1 (fr) * 1993-08-06 1996-07-31 Smithkline Beecham Corporation Antagonistes du recepteur de l'endotheline
WO1995004530A1 (fr) * 1993-08-06 1995-02-16 Smithkline Beecham Corporation Antagonistes du recepteur d'endotheline
US5714479A (en) * 1993-08-18 1998-02-03 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
CN1049219C (zh) * 1993-08-18 2000-02-09 万有制药株式会社 具有内皮素拮抗活性的芳香杂环并环戊烯衍生物
US5389620A (en) * 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
WO1997007119A1 (fr) * 1994-08-26 1997-02-27 Takeda Chemical Industries, Ltd. Derives de thienopyrimidine, leur fabrication et leurs applications
US6140325A (en) * 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
RU2126418C1 (ru) * 1993-11-01 1999-02-20 Циба-Гейги Джапан Димитед Антагонисты рецепторов эндотелина
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US6075037A (en) * 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
EP0768878A4 (fr) * 1994-06-20 1999-02-17 Smithkline Beecham Corp Antagonistes des recepteurs de l'endotheline
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
ATE219077T1 (de) * 1994-08-19 2002-06-15 Abbott Lab Endothelin antagoniste
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
EP0799225A4 (fr) * 1994-12-23 1998-03-25 Smithkline Beecham Corp Composes et procedes associes
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
DE59603464D1 (de) * 1995-06-30 1999-12-02 Cerbios Pharma Sa Glykoside, deren zuckerfreie Abbauprodukte und Derivate derselben
DE19527568A1 (de) * 1995-07-28 1997-01-30 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
DE19530032A1 (de) * 1995-08-16 1997-02-20 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19537548A1 (de) * 1995-10-09 1997-04-10 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
JP2000500443A (ja) * 1995-11-08 2000-01-18 スミスクライン・ビーチャム・コーポレイション ３−フェニル−１−メチレンジオキシフェニル−インダン−２−カルボン酸誘導体の製造プロセス
ZA969363B (en) 1995-11-08 1997-11-18 Smithkline Beecham Corp An improved process for preparing aromatic ring-fused cyclopentane derivatives.
WO1997017071A1 (fr) * 1995-11-08 1997-05-15 Smithkline Beecham Corporation Synthese stereoselective d'antagonistes de recepteurs d'endothelines
US6162932A (en) * 1995-11-08 2000-12-19 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
US6080862A (en) * 1995-11-08 2000-06-27 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
WO1997017342A1 (fr) * 1995-11-08 1997-05-15 Smithkline Beecham Corporation Procede pour la production de derives d'acide 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylique
DE19543639A1 (de) * 1995-11-23 1997-05-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
WO1997030045A1 (fr) * 1996-02-13 1997-08-21 Abbott Laboratories Derives de pyrrolidine a substitution benzo-1,3-dioxolyl et benzofuranyl servant d'antagonistes de l'endotheline
JP2000504727A (ja) * 1996-02-13 2000-04-18 アボット・ラボラトリーズ エンドセリン拮抗物質としての４―（ベンゾ―１，３―ジオキソリル）―ピロリジン―３―カルボン酸誘導体
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
CZ263098A3 (cs) 1996-02-20 1999-05-12 Bristol-Myers Squibb Company Způsoby přípravy bifenylisoxazolsulfonamidů
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
JP2000514060A (ja) * 1996-07-01 2000-10-24 シェーリング コーポレイション ムスカリン様アンタゴニスト
US6172235B1 (en) 1996-08-09 2001-01-09 Merck & Co., Inc. Asymmetric conjugate addition reaction
WO1998006700A1 (fr) * 1996-08-09 1998-02-19 Merck & Co., Inc. Reaction de desoxygenation stereoselective
JP3262805B2 (ja) * 1996-08-09 2002-03-04 メルク エンド カンパニー インコーポレーテッド 非対称性共役付加反応
US6218427B1 (en) 1996-08-27 2001-04-17 Shionogi & Co., Ltd. Chromene-3-carboxylate derivatives
DE19653024A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5998625A (en) * 1997-01-14 1999-12-07 Merck & Co., Inc. Asymmetric conjugate addition reaction using a chiral additive
TW432028B (en) * 1997-01-14 2001-05-01 Merck & Co Inc Asymmetric conjugate addition reaction using a chiral additive
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998033781A1 (fr) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Procede pour prevenir ou traiter l'hypertension due a une baisse de secretion de la renine, par l'administration d'un antagoniste de l'endotheline
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6013674A (en) * 1997-06-02 2000-01-11 Eli Lilly And Company Cell adhesion inhibitors
JP4058507B2 (ja) 1997-07-10 2008-03-12 国立大学法人 東京医科歯科大学 ４，５−ジヒドロ−［１Ｈ］−ベンズ［ｇ］インダゾール−３−カルボン酸誘導体
US6022972A (en) * 1997-08-08 2000-02-08 Merck & Co., Inc. Pyridine propanoic acid derivatives
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
ATE259800T1 (de) * 1998-01-21 2004-03-15 Banyu Pharma Co Ltd Substituierte 5-(2,2difluor-1,3-benzodioxol-5-yl) cyclopentenopyridinderivate
AR022230A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
EP1165472A4 (fr) 1999-03-19 2002-11-20 Bristol Myers Squibb Co Procedes pour la preparation de diphenylisoxazolesulfonamides
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
EP1180094B1 (fr) * 1999-05-26 2004-07-28 Warner-Lambert Company Acides amines polycycliques accoles utilises comme agents pharmaceutiques
AU5667900A (en) 1999-06-30 2001-01-22 Prescient Neuropharma Inc. 2-aminoindane analogs
ES2285334T3 (es) 1999-12-31 2007-11-16 Encysive Pharmaceuticals, Inc Sulfonamidas y sus derivados como moduladores de la actividad de endotelina.
EP1461323B1 (fr) 2001-06-12 2013-10-09 Wellstat Therapeutics Corporation Composes destines au traitement de troubles metaboliques
EP1658276B1 (fr) 2003-08-18 2012-10-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
KR100595963B1 (ko) * 2004-04-13 2006-07-05 한국화학연구원 인덴 유도체 및 이의 제조방법
ES2314749T3 (es) 2004-12-21 2009-03-16 F. Hoffmann-La Roche Ag Derivados de tetralina y de indano y usos de los mismos como antagonistas de 5-ht.
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
NZ599605A (en) 2007-02-19 2013-11-29 Marinepolymer Tech Inc Hemostatic compositions and therapeutic regimens
NZ602909A (en) 2010-04-15 2015-01-30 Marinepolymer Tech Inc Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
CA2832859C (fr) 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Traitement de maladies avec des nanofibres de poly-n-acetylglucosamine
CN110343038B (zh) * 2018-04-02 2022-03-15 暨南大学 一种宝乐果单体、提取物及其制备方法和应用
IL309666A (en) 2021-07-09 2024-02-01 Plexium Inc Aryl compounds and pharmaceutical preparations that modulate IKZF2
WO2024005578A1 (fr) * 2022-06-29 2024-01-04 아밀로이드솔루션 주식회사 Nouveaux dérivés d'indénone et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642785A (en) * 1969-08-11 1972-02-15 Merck & Co Inc Indenyl-3-aliphatic amines
US3737455A (en) * 1971-01-21 1973-06-05 Merck & Co Inc Substituted 1-(loweralkyl-sulfinylbenzylidene)-3-indenyloxyacetic acid and esters thereof
US4224341A (en) * 1976-01-12 1980-09-23 Lipha, Lyonnaise Industrielle Pharmaceutique 5-Substituted indan-2 carboxylic acid and functional derivatives
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
JPS61197557A (ja) * 1985-02-27 1986-09-01 Sankyo Co Ltd インダン誘導体およびその製法
IT1190371B (it) * 1985-06-19 1988-02-16 Zambon Spa Processo per la preparazione dell'acido cis-5-fluoro-2-metil-1-(4-metiltiobenziliden)-indenil-3-acetico

Also Published As

Publication number Publication date
CN1145223A (zh) 1997-03-19
EP0612244A1 (fr) 1994-08-31
BR9206722A (pt) 1995-07-18
ATE205711T1 (de) 2001-10-15
KR100342960B1 (fr) 2003-02-11
WO1993008799A1 (fr) 1993-05-13
DE69232072D1 (de) 2001-10-25
PT101038B (pt) 1999-07-30
JPH07501322A (ja) 1995-02-09
MY108579A (en) 1996-10-31
EP0612244A4 (fr) 1995-05-17
CZ287406B6 (cs) 2000-11-15
CZ110994A3 (en) 1995-01-18
AP433A (en) 1995-11-17
AU669866B2 (en) 1996-06-27
CN1034569C (zh) 1997-04-16
HK1012251A1 (en) 1999-07-30
RU2125980C1 (ru) 1999-02-10
HU9401319D0 (en) 1994-08-29
PT101038A (pt) 1994-02-28
PL176250B1 (pl) 1999-05-31
SI9200297A (en) 1993-06-30
FI942059A (fi) 1994-07-04
BG98752A (bg) 1995-05-31
UA44686C2 (uk) 2002-03-15
HUT67665A (en) 1995-04-28
CA2122820A1 (fr) 1993-05-13
IL103621A0 (en) 1993-04-04
ES2164054T3 (es) 2002-02-16
EP0612244B1 (fr) 2001-09-19
CN1073161A (zh) 1993-06-16
JP2667294B2 (ja) 1997-10-27
NO941650L (no) 1994-07-01
NO304887B1 (no) 1999-03-01
SK282098B6 (sk) 2001-11-06
DK0612244T3 (da) 2002-01-14
DE69232072T2 (de) 2002-06-20
NO941650D0 (no) 1994-05-04
SK52194A3 (en) 1995-03-08
AU3125993A (en) 1993-06-07
MX9206348A (es) 1994-06-30
AP9200440A0 (en) 1993-01-31
FI942059A0 (fi) 1994-05-04
MA22758A1 (fr) 1993-10-01
BG61523B1 (en) 1997-11-28
NZ245000A (en) 1996-05-28
OA09921A (en) 1994-08-15
TW298590B (fr) 1997-02-21
RO117847B1 (ro) 2002-08-30

Similar Documents

Publication Publication Date Title
SI9200297B (sl) Antagonisti endotelinskih receptorjev
SI9400195B (sl) Antagonisti endotelinskih receptorjev
RU95122388A (ru) Антагонисты эндотелинового рецептора
CA2040955A1 (fr) Derives du benzimidazole, leur production et leur utilite
AR044981A1 (es) Combinacion de un inhibidor alosterico de metaloproteinasa de matriz 13 (mmp-13) y un ligando de un receptor alfa-2- delta
RU99109576A (ru) Амины аминотиофенкарбоновой кислоты и их применение
RU97106022A (ru) Лиганды x-рецептора ретиноевой кислоты
FR2800375B1 (fr) Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
RU99119223A (ru) Бициклические автоматические аминокислоты
DE69032414D1 (de) Diphenylmethane derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
EP1413576A3 (fr) Dérivés d'imidazoles substituées et leur utilisation en tant qu'agonistes des récepteurs adrénergiques alpha 2B ou 2B/2C
EA200000682A1 (ru) Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов
ES2101824T3 (es) N-acil-n-heterociclil-onaftalenil-alquil-aminoacidos como antagonistas de angiotensina ii.
KR890008072A (ko) 벤조사이클로헵텐 유도체
EA200200952A1 (ru) Производные циклогексиламина в качестве селективных антагонистов подтипов nmda-рецепторов
SK391292A3 (en) 4-alkyimidazole derivatives
EP0309422A3 (fr) Dérivés amidino tricycliques
ATE320424T1 (de) Verfahren zu herstellung von citalopram
RU2001114188A (ru) Производные хроменона и хроманона в качестве ингибиторов интегринов
RU94020400A (ru) Производные индола, способ их получения, фармацевтическая композиция, способ лечения головной боли
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
NO943231L (no) Aromatiske karboksylsyrederivater
BR9917205A (pt) Antagonistas de retinóides e seu uso
EP0351385A3 (fr) Dérivés d'amidino et de guanidino
DK0542554T3 (da) Substituerede N-biphenylyllactamer

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20100611